Suramin inhibits the binding of complement-fixing antibody/double-stranded DNA immune complexes to CR1.
The effects of varying concentrations of heparin and suramin on the complement-mediated binding of antibody/double-stranded DNA immune complexes to red blood cells (RBCs) and Raji cells have been investigated. If the immune complexes are briefly opsonized with complement, suramin can block binding to both cell types, and heparin can block binding to RBCs. In addition, if these complexes are first allowed to bind to RBCs or Raji cells, relatively brief incubations in suramin are sufficient to cause release of the complexes from the cells' C3b receptors. The potential clinical and diagnostic implications of these findings are discussed.
D000906:Antibodies; D000936:Antigen-Antibody Complex / Q000378:metabolism*; D001666:Binding Sites, Antibody / Q000187:drug effects*; D003165:Complement System Proteins / Q000276:immunology; D004247:DNA / Q000276:immunology*; D004912:Erythrocytes / Q000276:immunology; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D009895:Opsonin Proteins; D011951:Receptors, Complement / Q000276:immunology*; D013498:Suramin / Q000494:pharmacology*
D000906:Antibodies; D000936:Antigen-Antibody Complex; D009895:Opsonin Proteins; D011951:Receptors, Complement; D013498:Suramin; D006493:Heparin; D003165:Complement System Proteins; D004247:DNA